These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

654 related items for PubMed ID: 21613799

  • 21. Low level STK15 amplification in histologically benign urothelium of patients with bladder cancer adversely predicts patient outcome following cystectomy.
    Denzinger S, Stoehr R, Schwarz S, Eichenseher N, Brockhoff G, Obermann EC, Knuechel R, Blaszyk H, Hartmann A, Wild PJ.
    Int J Oncol; 2007 Oct; 31(4):793-802. PubMed ID: 17786310
    [Abstract] [Full Text] [Related]

  • 22. Comparison of p38MAPK (mitogene activated protein kinase), p65 NFkappaB (nuclear factor kappa b) and EMMPRIN (extracellular matrix metalloproteinase inducer) expressions with tumor grade and stage of superficial and invasive bladder tumors.
    Ozbek E, Otunctemur A, Calik G, Aliskan T, Cakir S, Dursun M, Somay A.
    Arch Ital Urol Androl; 2011 Dec; 83(4):181-7. PubMed ID: 22670315
    [Abstract] [Full Text] [Related]

  • 23. Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas.
    Donmez G, Sullu Y, Baris S, Yildiz L, Aydin O, Karagoz F, Kandemir B.
    Pathol Res Pract; 2009 Dec; 205(12):854-7. PubMed ID: 19762163
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. SOX4 expression levels in urothelial bladder carcinoma.
    Gunes S, Yegin Z, Sullu Y, Buyukalpelli R, Bagci H.
    Pathol Res Pract; 2011 Jul 15; 207(7):423-7. PubMed ID: 21680105
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.
    Caprodossi S, Lucciarini R, Amantini C, Nabissi M, Canesin G, Ballarini P, Di Spilimbergo A, Cardarelli MA, Servi L, Mammana G, Santoni G.
    Eur Urol; 2008 Sep 15; 54(3):612-20. PubMed ID: 17977643
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
    Korkolopoulou P, Givalos N, Saetta A, Goudopoulou A, Gakiopoulou H, Thymara I, Thomas-Tsagli E, Patsouris E.
    Hum Pathol; 2005 Aug 15; 36(8):899-907. PubMed ID: 16112007
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter.
    Inoue K, Kamada M, Slaton JW, Fukata S, Yoshikawa C, Tamboli P, Dinney CP, Shuin T.
    Clin Cancer Res; 2002 Jun 15; 8(6):1863-70. PubMed ID: 12060629
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study.
    Samaratunga H, Khoo K.
    Histopathology; 2004 Jul 15; 45(1):55-64. PubMed ID: 15228444
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
    Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, Fradet Y, Lacombe L, Kwon ED.
    Cancer; 2007 Apr 15; 109(8):1499-505. PubMed ID: 17340590
    [Abstract] [Full Text] [Related]

  • 36. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
    Gandour-Edwards R, Lara PN, Folkins AK, LaSalle JM, Beckett L, Li Y, Meyers FJ, DeVere-White R.
    Cancer; 2002 Sep 01; 95(5):1009-15. PubMed ID: 12209684
    [Abstract] [Full Text] [Related]

  • 37. Decreased galectin-8 is a strong marker for recurrence in urothelial carcinoma of the bladder.
    Kramer MW, Waalkes S, Serth J, Hennenlotter J, Tezval H, Stenzl A, Kuczyk MA, Merseburger AS.
    Urol Int; 2011 Sep 01; 87(2):143-50. PubMed ID: 21757871
    [Abstract] [Full Text] [Related]

  • 38. Calcifying Cystic Odontogenic Tumour: immunohistochemical expression of matrix metalloproteinases, their inhibitors (TIMPs and RECK) and inducer (EMMPRIN).
    Prosdócimi FC, Rodini CO, Sogayar MC, Sousa SC, Xavier FC, Paiva KB.
    J Oral Pathol Med; 2014 Aug 01; 43(7):545-53. PubMed ID: 24484176
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C, von Struensee D, Bierer S, Bögemann M, Hertle L, Eltze E.
    Aktuelle Urol; 2005 Sep 01; 36(5):423-9. PubMed ID: 16163605
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.